1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Neurogastrx Shows It Can Offset GLP-1 Side Effects

Firm Thinks Payers Will Cover An Add-On To Improve Compliance

 
• By Joseph Haas

A Phase II study shows that D2 receptor antagonist NG101 can significantly reduce nausea and vomiting in patients taking Novo Nordisk’s semaglutide for obesity.

Neurogastrx is looking to improve therapeutic compliance in patients taking GLP-1 agonists (Shutterstock)

Privately held Neurogastrx thinks it has a potential blockbuster with a Phase II candidate that can reduce the nausea and vomiting associated with GLP-1 therapies for obesity, type 2 diabetes and other indications – and it thinks payers will support add-on therapy that could improve adherence to GLP-1s.

Key Takeaways
  • Neurogastrx said its D2 receptor antagonist shows an ability to reduce nausea and vomiting in patients taking semaglutide for weight loss.
  • The privately held company sees a blockbuster revenue opportunity because of frequent GLP-1 treatment discontinuations due to GI side effects

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.